On February 9, the FDA sent out a number of warning letters to companies that make and sell products containing cannabidiol (CBD), a type of cannabinoid found in marijuana. Some of the products that the FDA tested contained no CBD in them at all.
Even more troubling, many of the products claim to be treatments for serious diseases and suggest that patients go into remission once they take the CBD product. The FDA is concerned that patients may believe these claims and delay seeing a doctor and taking approved drugs with a proven track record.
“The FDA is in the business of regulating claims. The more claims you make the more scrutiny you’ll face,” said Seth Yakatan, Chief Executive Officer of Kalytera, a company that is creating a synthetic form of CBD.
– Read the entire article at Forbes.